BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12460055)

  • 1. Fanconi syndrome and renal failure induced by tenofovir: a first case report.
    Verhelst D; Monge M; Meynard JL; Fouqueray B; Mougenot B; Girard PM; Ronco P; Rossert J
    Am J Kidney Dis; 2002 Dec; 40(6):1331-3. PubMed ID: 12460055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature.
    Malik A; Abraham P; Malik N
    J Infect; 2005 Aug; 51(2):E61-5. PubMed ID: 16038754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
    Karras A; Lafaurie M; Furco A; Bourgarit A; Droz D; Sereni D; Legendre C; Martinez F; Molina JM
    Clin Infect Dis; 2003 Apr; 36(8):1070-3. PubMed ID: 12684922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].
    de la Prada FJ; Prados AM; Tugores A; Uriol M; Saus C; Morey A
    Nefrologia; 2006; 26(5):626-30. PubMed ID: 17117909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    Rifkin BS; Perazella MA
    Am J Med; 2004 Aug; 117(4):282-4. PubMed ID: 15308442
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
    Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
    Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
    Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
    AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.
    Rollot F; Nazal EM; Chauvelot-Moachon L; Kélaïdi C; Daniel N; Saba M; Abad S; Blanche P
    Clin Infect Dis; 2003 Dec; 37(12):e174-6. PubMed ID: 14689363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution.
    Gaspar G; Monereo A; García-Reyne A; de Guzmán M
    AIDS; 2004 Jan; 18(2):351-2. PubMed ID: 15075563
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
    Brim NM; Cu-Uvin S; Hu SL; O'Bell JW
    AIDS Read; 2007 Jun; 17(6):322-8, C3. PubMed ID: 17632940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tenofovir (Viread)].
    Sidahora; 2002; (1):20-1. PubMed ID: 12772661
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient.
    Perrot S; Aslangul E; Szwebel T; Caillat-Vigneron N; Le Jeunne C
    J Clin Rheumatol; 2009 Mar; 15(2):72-4. PubMed ID: 19265350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
    [No Abstract]   [Full Text] [Related]  

  • 14. [Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir].
    Kuijper A; Rookmaker MB; Mudrikova T
    Ned Tijdschr Geneeskd; 2011; 155():A2249. PubMed ID: 21418698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
    MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.
    Jaafar A; Séronie-Vivien S; Malard L; Massip P; Chatelut E; Tack I
    AIDS; 2009 Jan; 23(2):257-9. PubMed ID: 19098496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.
    Quimby D; Brito MO
    AIDS Read; 2005 Jul; 15(7):357-64. PubMed ID: 16044577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate.
    Gallant JE; Deresinski S
    Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS
    AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
    Atta MG; Fine DM
    AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.